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Available online 11 April 2013Abstract Glioblastoma is the most common and aggressive primary brain tumor. Glioma stem cells (GSCs) are relatively
resistant to chemo-radiotherapy and are responsible for tumor progression and the recurrence of glioblastomas after
conventional therapy. Thus, the control of the GSC population is considered key to realizing long-term survival of glioblastoma
patients. Here, we identified that resveratrol significantly reduced the self-renewal and tumor-initiating capacity of
patient-derived GSCs. Furthermore, resveratrol promoted Nanog suppression via proteasomal degradation, which was inhibited
by MG132, a proteasome inhibitor. p53 activation is an important factor in Nanog suppression and treatment with resveratrol
was also found to activate the p53/p21 pathway. Importantly, inhibition of Nanog by siRNA provoked inhibitory effects on both
the self-renewal and tumor-forming capacity of GSCs. Our findings indicate that Nanog is an essential factor for the retention
of stemness and may contribute to the resveratrol-induced differentiation of GSCs. Our results also suggest that targeting GSCs
via the p53–Nanog axis, with resveratrol for instance, could be a therapeutic strategy against glioblastoma.
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Glioblastoma is the most common primary brain tumor in
adults and is one of the most deadly and least successfully
treated solid tumors (Stupp et al., 2009, 2005). The
treatment of this tumor currently involves a combination of
surgery, radiotherapy, and chemotherapy (Stupp et al.,
602 A. Sato et al.2009, 2005; Wen and Kesari, 2008); however, this approach is
eventually ineffective, and most patients die within 2 years
because of tumor recurrence. Therapeutic resistance might
occur due to multiple factors, but many recent studies have
suggested that a tumorigenic subpopulation of cancer cells,
termed cancer stem cells, tumor-initiating cells, or cancer
stem-like cells, is highly resistant to radiotherapy and chemo-
therapy (Bao et al., 2006; Li et al., 2008; Liu et al., 2006;
Todaro et al., 2007; Zhang et al., 2008). Glioma stem cells
(GSCs), or the so-called glioma-initiating cells, express stem
cell markers and have self-renewal capacity, i.e., they have
the potential to differentiate into multiple lineages and
generate tumors reproducing the characteristics of the
original tumor (Park and Rich, 2009). We and others have
shown that GSCs contribute to therapeutic resistance, such as
resistance to radiotherapy and chemotherapy (Bao et al.,
2006; Bleau et al., 2009; Liu et al., 2006; Sato et al., 2011).
Current evidence on therapeutic resistance suggests the
critical role of GSCs in tumor maintenance and recurrence
(Rich and Bao, 2007; Sato et al., 2010). Therefore, novel
therapies targeting this subpopulation of cells may significantly
improve the outcome of glioblastoma patients (Liu et al., 2006;
Zhou et al., 2009).
Many studies have demonstrated that GSCs isolated from
glioblastomas display a capacity for multiple-lineage differ-
entiation (Hemmati et al., 2003; Matsuda et al., 2012; Singh
et al., 2003, 2004; Sunayama et al., 2010b). When differen-
tiated, these cells usually lose the capacity for long-term
cellular repopulation and fail to propagate tumors, suggesting
that inducing differentiation in GSCs may be a practical
strategy for eliminating the GSC population (Frank et al.,
2010). In addition, the possibility that the differentiation of
GSCs within a malignancy can lead to tumor degeneration and
increased susceptibility to conventional cytotoxic therapies
has been widely recognized (Frank et al., 2010). Thus, it is
very important to elucidate the mechanisms underlying the
control of stem cells and cancer stem cell differentiation. In
this respect, several strategies have been reported to promote
the differentiation of GSCs (Ikushima et al., 2009; Lee et al.,
2008; Matsuda et al., 2012; Penuelas et al., 2009; Piccirillo
et al., 2006; Sato et al., 2012; Sunayama et al., 2011). All
these reports demonstrate that the promotion of GSC
differentiation can markedly reduce their tumorigenicity and
thereby control the GSC population per se, underscoring the
idea that differentiation therapy is a promising approach to
target GSCs.
Resveratrol is a phytochemical found in many natural foods
such as red wine, grapes, and peanuts (Baur and Sinclair,
2006). The antitumor effect of resveratrol has been demon-
strated in many cancers, and it has been shown to regulate
multiple stages of tumorigenesis, including the prevention of
tumor initiation (Athar et al., 2007; Bishayee, 2009). While it
is also well recognized that cancer stem cells play a key role in
tumor initiation (Reya et al., 2001), the effects of resveratrol
on cancer stem cells remain poorly understood.
Nanog is considered a master transcriptional factor of
embryonic stem cells (ESCs). Nanog expression is modulated
at the transcriptional level, positively regulated by LIF-STAT3
and bone morphogenetic protein-Brachyury pathways, and
negatively regulated by transcription factor 3 and p53 (Lin
et al., 2005; Pan and Thomson, 2007). Recent evidence has
suggested a shared characteristic between ESCs, cancer cells,and cancer stem cells (Boyer et al., 2005). Nanog may play
important functions in the development and progression of
malignant tumors; however, this has not been fully
understood.
Here, we provide evidence that resveratrol promotes
differentiation and suppresses the tumorigenicity and self-
renewal capacity of GSCs. We demonstrated that Nanog is a
key factor for GSC maintenance and that resveratrol
suppresses Nanog expression. We also demonstrated that
resveratrol induces p53 phosphorylation-dependent activa-
tion, which is crucial to Nanog degradation in GSCs. This
study thus offers novel opportunities to develop molecular
targeting drugs for the p53–Nanog pathway, which may
overcome the therapeutic resistance of GSCs. Our findings
also suggest that resveratrol could be an effective therapeutic
agent in the treatment of glioblastoma.
Materials and methods
Reagents and antibodies
Resveratrol was purchased from Sigma-Aldrich. Epidermal
growth factor (EGF) and basic fibroblast growth factor
(bFGF) were from PeproTech.
The following antibodies were used: Nestin (AB5922),
Bmi1 (05-637), Neurofilament-H (MAB5446), and p53 (OP-43)
from Millipore; Sox2 (MAB2018), GFAP (AF2594), and βIII-
tubulin (MAB1195) from R&D Systems; phospho-histone H2AX
(#9718), phospho-p53 (#9284), p21 (#2947), andNanog (#4903)
from Cell Signaling Technology; Musashi (ab21628) from
Abcam; and Actin (AC-15) from Sigma-Aldrich. Horseradish
peroxidase (HRP)-conjugated secondary antibodies for immu-
noblotting were purchased from Jackson ImmunoResearch
Laboratories. Alexa 488-conjugated secondary antibodies for
immunofluorescence were from Invitrogen.
Culture of patient-derived GSCs
Isolation, establishment, and maintenance of patient-derived
GSC cultures were carried out as previously described
(Matsuda et al., 2012; Sato et al., 2012; Sunayama et al.,
2010a) with approval from the Institutional Review Boards of
Yamagata University, School of Medicine. Characterization of
the stem cell properties of the cells used in this study has been
described in several studies (Matsuda et al., 2012; Sato et al.,
2011, 2012; Sunayama et al., 2011).
Sphere formation assay
Sphere formation assays were performed as described else-
where (Matsuda et al., 2012; Sato et al., 2012). For primary
sphere formation assays, cells were dissociated and suspended
in stem cell culture medium at a density of 5 × 103 cells/ml;
200 μl of the cell suspension was then transferred to each well
of a non-coated 96-well plate. To assay secondary sphere
formation, primary tumor spheres formed by cells seeded onto
non-coated 35-mm dishes at a density of 5 × 103 cells/ml in
stem cell culture medium were collected 3 days after seeding
and were dissociated, after which 200 μl of the cell suspension
was transferred to each well of a non-coated 96-well plate.
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using suspensions of secondary tumor sphere cells formed on
non-coated 35-mm dishes by cells from primary tumor spheres
that had been seeded at a density of 5 × 103 cells/ml. Using
phase-contrast microscopy, the number of tumor spheres
formed on 96-well plates was counted 3 days after seeding.Gene silencing by siRNA
siRNAs against human Nanog (#1: HSS188276, #2: HSS188277),
p53 (#1: HSS110905, #2: HSS186390), and non-targeting
control (12935112) were purchased from Invitrogen. Transfec-
tion of siRNAs was performed using Lipofectamine RNAi MAX
(Invitrogen), according to the manufacturer's instructions.Immunoblot analysis
To obtain whole-cell lysates, cells were lysed in lysis buffer
(10 mMTris–HCl [pH 7.4], 0.1% SDS, 1% sodiumdeoxychlolate,
0.15 M NaCl, 1 mM EDTA, and 1% protease inhibitor cocktail
set III [Calbiochem]). For analysis of phosphorylated proteins,
the lysis buffer was supplemented with phosphatase inhibitors
(20 mM β-glycerophosphate, 10 mM NaF, and 0.1 mM
Na3VO4). After determination of protein concentrations using
a BCA protein assay kit (Pierce), cell lysates containing equal
amounts of protein were separated by SDS-PAGE and trans-
ferred to a polyvinylidene difluoride membrane. The mem-
brane was probed with a primary antibody and then with an
appropriate HRP-conjugated secondary antibody, according to
the protocol recommended by the manufacturer of each
antibody. Blots were visualized using Immobilon Western
chemiluminescent HRP substrate (Millipore) or ECL Western
blotting detection reagents (GE Healthcare).Immunofluorescence analysis
Cells were plated onto coated glass coverslips and fixed with
4% paraformaldehyde in phosphate-buffered saline (PBS) for
15 min at room temperature. The fixed cover slips were
permeabilized in 0.5% Triton X-100 for 5 min, washed twice
with PBS, and incubated in a blocking solution (PBS containing
2% bovine serum albumin and 2% fetal bovine serum) for
30 min. The cells were then incubated in this blocking solution
with primary antibodies at 4 °C overnight, followed by
incubation with Alexa Fluor 488-conjugated secondary anti-
bodies in blocking solution for 1 h at room temperature.
Stained cells were observed with an epifluorescence micro-
scope (CKX41, Olympus) equipped with a CCD camera system
(DP-30BW, Olympus). Fluorescence images were processed
using Photoshop CS5.1 (Adobe).RT-PCR analysis
Total RNA was extracted with TRIzol (Invitrogen). Total RNA
was reverse-transcribed into cDNA using M-MLV (Invitrogen)
according to the manufacturer's instructions.
Amplification was performed with cycles of 98 °C for
1 min, 60 °C for 30 s, and 72 °C for 1 min in a thermal cycler
(TaKaRa PCR Thermal Cycler Dice). PCR cycle numbers were28 for Nanog and 25 for Gapdh. RT-PCR analysis was
performed with the following primers:
Nanog (F: 5′-TTGGAGCCTAATCAGCGAGGT-3′, R: 5′-GCCT
CCCAATCCCAAACAATA-3′).
Gapdh (F: 5′-TCCTGTTCGACAGTCAGCCGCATCTT-3′, R: 5′-
GACCAGGCGCCCAATACGACCAA-3′).
Mouse xenograft models
Intracranial xenograft models were created by injecting
GSCs suspended in phosphate-buffered saline into the corpus
striatum of 5-week-old male BALB/cAJcl-nu/nu mice, as
described previously (Matsuda et al., 2012; Sato et al., 2012).
All animal experiments were performed according to a
protocol approved by the Animal Research Committee of
Yamagata University.
Statistical analysis
Data are expressed as mean ± SD. Differences were com-
pared using two-tailed Student's t-tests. Mouse survival was
evaluated by the Kaplan–Meier method and analyzed using
the log-rank test. P-values less than 0.05 were considered
statistically significant.
Results
Resveratrol inhibits self-renewal capacity and
promotes the differentiation of glioma stem cells
Resveratrol has antitumor effects inmany types of cancers and
has been shown to modulate various steps of tumorigenesis,
such as initiation, progression, and metastasis (Athar et al.,
2007; Bishayee, 2009). To determine whether resveratrol also
affects GSCs, we first tested the effect of resveratrol on the
sphere-forming capacity of primary human GSCs. Resveratrol
treatment reduced sphere formation, suggesting impairment
of GSC self-renewal capacity (Figs. 1A and B).
To determine whether inhibition in sphere-forming
capacity results in the loss of stem cell characteristics, we
examined the expression of stem cell and differentiation
markers. Resveratrol treatment reduced the expression of
stem cell markers such as Nestin, Musashi, and Sox2 (Fig. 1C).
At the same time, resveratrol treatment increased the
expression of differentiation markers such as Neurofilament-
H (NF-H; a neural marker) and glial fibrillary acidic protein
(GFAP; an astrocyte marker) (Fig. 1C). Immunofluorescence
analysis also revealed that the numbers of cells positive for
neural marker βIII-tubulin and GFAP increased after resvera-
trol treatment (Figs. 1D and S1). These results demonstrated
that resveratrol treatment inhibits the self-renewal capacity
of GSCs and induces their differentiation.
Nanog is essential for the retention of stemness of
glioma stem cells
To elucidate the mechanism of resveratrol-induced differen-
tiation of GSCs, we first examined a time-course of stem cell/
differentiation marker expression. Decreased expression of
Figure 1 Resveratrol treatment inhibits the self-renewal capacity and induces differentiation of glioma stem cells. (A, B): The
indicated glioma stem cells (GSCs) were cultured in the presence of either resveratrol (50 μM) or vehicle (DMSO) for 3 days and were
then subjected to sphere formation assays in the absence of resveratrol. (A): Representative photomicrographs of spheres formed by
GSCs. Scale bars: 200 μM. (B): The number of spheres formed (mean ± SD from 3 independent experiments). *P b 0.05. (C): The
indicated GSCs were cultured in the presence of either resveratrol (50 μM) or vehicle (DMSO) for 3 days, before being subjected to
immunoblot analysis of NSC/progenitor (Nestin, Sox2, and Musashi) and differentiation (GFAP and NF-H) markers. (D): GS-Y03 cells
were cultured in the presence of either resveratrol (50 μM) or vehicle (DMSO) for 3 days. Next, they were subjected to
immunofluorescence analysis for differentiation marker expression. Representative fluorescence images of GFAP and βIII-tubulin
expression (green) are shown. Nuclei were counterstained with Hoechst 33342 (blue). Scale bars: 100 μM. Abbreviations: DMSO,
dimethyl sulfoxide; RSV, resveratrol; 1st, primary; 2nd, secondary; 3rd, tertiary; GFAP, glial fibrillary acidic protein; and NF-H,
Neurofilament-H.
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treatment, but other stem cell markers had not decreased
by that time (Figs. 2A and S2A). These results suggested that
the downregulation of Nanog plays a causative and important
role in resveratrol-induced GSC differentiation. Nanog func-
tion has been shown to be required to sustain high prolifer-
ating levels of CD133-positive glioblastoma cells in vitro and invivo (Zbinden et al., 2010). However, it is unclear how Nanog
expression affects stem cell and differentiation markers.
To study the role of Nanog in GSCs, we first examined the
effects of Nanog-knockdown on the biological properties of
these cells. After Nanog expression was knocked down using
2 different siRNAs, GSCs exhibited marked reduction of
sphere formation, as well as of stem cell marker expression
Figure 2 Nanog is required for the retention of stemness in glioma stem cells. (A) GS-Y03 cells were treated with or without
resveratrol (50 μM) or vehicle (DMSO) for the indicated periods. Cell lysates were subjected to immunoblot analysis using the
indicated antibodies. (B–C) GS-Y03 cells were transfected with non-targeting siRNA (control) or with siRNAs against Nanog (#1 or #2).
After 3 days, the transfected cells were subjected to sphere formation (B) and immunoblot assays (C). The data represent mean ± SD
from 3 independent experiments. (D–E) GS-Y03 cells were transfected with non-targeting siRNA (control) or with siRNAs against
Nanog (#1 or #2). At 3 days after transfection, the cells (1 × 104) were injected intracranially into BALB/cAJcl2 nu/nu mice.
(D): Representative hematoxylin and eosin stainings of brain sections frommice sacrificed 30 days after implantation. (E): Kaplan–Meier
plot showing survival of mice (5 mice per group) after intracranial implantation. *P b 0.05. Abbreviations: RSV, resveratrol; 1st, primary;
2nd, secondary; siRNA, small interfering RNA; GFAP, glial fibrillary acidic protein; and NF-H, Neurofilament-H.
605p53-Nanog pathway regulates glioma stem cells(Figs. 2B and C, S2B and C). In parallel, knockdown of Nanog
increased the expression of differentiation markers (Figs. 2C
and S2C).
Finally, we determined whether the promoted differen-
tiation of GSCs, brought about by the knockdown of Nanog,resulted in the loss of their tumor-initiating potential, which
is an essential ability of cancer stem cells. Thus, GSCs with
or without Nanog-knockdown were implanted into the brains
of immunocompromised mice. Consistently, the recipient
mice survived significantly longer when they were implanted
606 A. Sato et al.with Nanog-knockdown GSCs than with GSCs without Nanog-
knockdown (Figs. 2D and E). These results indicated that
Nanog plays a pivotal role in the maintenance of GSCs and
that loss of tumorigenicity by Nanog-knockdown may be an
irreversible process. Moreover, these results suggested that
early Nanog downregulation may contribute to the inhibitory
effect of resveratrol in GSCs.Resveratrol treatment downregulates the stability
of Nanog protein
So far, we demonstrated that resveratrol induced loss of
self-renewal and differentiation of GSCs, and that Nanog has
a pivotal role in the maintenance of GSCs. These results
suggested that Nanog potentially plays a key role in the
impact of resveratrol on GSCs. However, any mechanistic
link between resveratrol treatment and Nanog suppression
was unclear. Thus, we performed a time-course analysis of
Nanog mRNA and protein expression. Interestingly, Nanog
protein levels were rapidly reduced in cells after 8 h of
resveratrol treatment, but NanogmRNA levels did not change
until 24 h after resveratrol treatment (Figs. 3A and B).
Nanog has been recently reported to bemodulated by post-
translational mechanisms in ESCs (Ramakrishna et al., 2011).
Therefore, we set out to determine whether resveratrol-
induced Nanog is largely concerned with the proteasome
pathway, as it is in ESCs. We found that MG132, a proteasome
inhibitor, rescued Nanog protein levels from the resveratrol-
induced downregulation (Fig. 3C). These results suggestedFigure 3 Resveratrol treatment promotes proteasomal degradatio
were cultured with resveratrol (50 μM) for the indicated periods, fo
examining Nanog mRNA. (C) GSCs were cultured with or without re
without MG132 (20 μM) for 4 h. Eight hours after resveratrol treatm
were analyzed. Abbreviations: RSV, resveratrol.that resveratrol suppresses Nanog expression by activating
proteasome-dependent degradation of Nanog protein.Activation of p53 is responsible for resveratrol-
mediated suppression of Nanog expression in glioma
stem cells
Although our findings indicated that resveratrol leads to
proteasomal degradation of Nanog, the molecular mechanism
by which this occurred remained unclear. In ESCs and induced
pluripotent stem cells (iPSCs), Nanog is a key regulator marker
of ESCs (Mitsui et al., 2003), and the p53/p21 pathway serves
as a barrier in iPSC generation (Hong et al., 2009). In addition,
resveratrol modulates phosphorylation of p53 at Ser 15,
resulting in p53 stabilization and increasing its functional
activity in mouse epidermal cells (She et al., 2001). These
studies together suggested that p53 may be associated with
changes in resveratrol-induced degradation of Nanog. We
tested whether p53, which is functionally active in GSCs
(Fig. S3), was phosphorylated after resveratrol treatment of
GSCs. We found that the level of p53 phosphorylation at Ser
15, together with its transcriptional target p21, was increased
after resveratrol treatment (Fig. 4A).
We next investigatedwhether p53 alsomediates resveratrol-
induced suppression of Nanog expression. We found that
resveratrol-induced suppression of Nanog was abolished by
p53-knockdown (Fig. 4B). These data together suggested that
resveratrol-induced suppression of Nanog expression is medi-
ated by p53 activation.n of Nanog in glioma stem cells. (A, B) Glioma stem cells (GSCs)
llowed by immunoblot analysis for Nanog protein and RT-PCR for
sveratrol (50 μM). Then, after 4 h, GSCs were treated with or
ent, cells were harvested and lysed, and Nanog and actin levels
Figure 4 p53 mediates resveratrol-induced Nanog downregulation in glioma stem cells. (A) Glioma stem cells (GSCs) were cultured
with resveratrol (50 μM) for the indicated periods, followed by immunoblot analysis to determine the expression levels of
phospho-p53 (Ser15), p53, p21, and phospho-histone H2AX. (B) GSCs were transfected first with siRNAs against p53 (#1 or #2) or with
non-targeting control, and then, 24 h later, cells were treated with or without resveratrol (50 μM) for 24 h. Cells were then analyzed
by immunoblotting with the indicated antibodies. Abbreviations: RSV, resveratrol; DMSO, dimethyl sulfoxide; and siRNA, small
interfering RNA.
607p53-Nanog pathway regulates glioma stem cellsResveratrol inhibits gliomagenesis initiated by glioma
stem cells
As resveratrol treatment efficiently induced the differenti-
ation of GSCs and depleted the pool of self-renewing GSCs, it
was deemed possible that resveratrol also plays a key role in
the control of their tumor-initiating potential. To test this
hypothesis, we injected vehicle (DMSO)- or resveratrol-
treated GSCs (1 × 104) intracranially into nude mice and
monitored the animals for brain tumor formation and survival.
After 30 days, the mice were sacrificed, and their brains were
examined for the presence of tumors. All animals receiving
vehicle-treated GSCs developed large tumor masses unlike
those that received resveratrol-treated GSCs (Fig. 5A).Furthermore, although all animals injected with vehicle-
treated GSCs died about 1 month after injection (median
survival, 31 days), animals injected with resveratrol-treated
GSCs survived significantly longer (median survival, 60 days)
(Figs. 5B and S4). Thus, resveratrol-induced differentiation of
GSCs abolished their tumor-initiating capacity in vivo.Discussion
The hypothesis that tumor cells with characteristics of stem
cells are responsible for tumor initiation, recurrence, and
therapeutic resistance is redirecting efforts against cancer
(Dick, 2008; Zhou et al., 2009). To date, several molecular
Figure 5 Resveratrol treatment suppresses tumor formation
and prolongs survival. GS-Y03 cells were cultured in the
presence of either resveratrol (50 μM) or vehicle (DMSO) for
3 days. These cells (1 × 104) were injected intracranially into
BALB/cAJcl2 nu/nu mice. (A): Representative hematoxylin and
eosin stainings of brain sections frommice sacrificed 30 days after
implantation. (B): Survival of mice (5 mice/group) was evaluated
by the Kaplan–Meier method. *P b 0.05. Abbreviations: DMSO,
dimethyl sulfoxide.
608 A. Sato et al.pathways for effective therapeutic targets against GSCs have
been identified (Ikushima et al., 2009; Lee et al., 2008;
Matsuda et al., 2012; Penuelas et al., 2009; Piccirillo et al.,
2006; Sato et al., 2012; Wurdak et al., 2010; Zheng et al.,
2010), but these agents are not applicable in a clinical setting.
Importantly, resveratrol has received increasing attention
for its potential therapeutic use, and several clinical trials
are currently underway (NCT00256334, NCT00433576, and
NCT00578396). However, in the cancer stem cell field, the
molecular mechanisms and effects of resveratrol have been
poorly understood to date. In this study, we have shown that
resveratrol may be effective in controlling GSCs.
In the present study, we found that resveratrol not only
inhibits the self-renewal capacity of GSCs (reduced sphere
formation and stemcellmarker expression) and tumorigenicity
but also promotes differentiation (increased differentiation
marker expression). Recently, resveratrol was shown to induce
apoptosis and suppress the growth of breast cancer stem-like
cells in vivo (Pandey et al., 2011). In gliomas, resveratrol
induced apoptosis and enhanced radiosensitivity of CD133-
positive glioblastoma cells (Yang et al., 2012). However, these
studies focused on the control of proliferation and enhance-
ment of the sensitivity of cancer stem cells to radio- and
chemotherapy; whether and how resveratrol regulated cancer
stem cell characteristics were not addressed. Here, we
demonstrated that the potential of resveratrol to differentiate
GSCs into non-tumorigenic cells and the resveratrol-induced
differentiation of these cells are important factors in inhibiting
the tumor-initiating capacity of cancer stem cells.We also showed that the transient suppression of Nanog
by siRNA annulled the self-renewal capacity and tumorigenic
activity of GSCs and induced the differentiation of these
cells. Recent evidence suggested a shared genomic finger-
print between ESCs, cancer cells, and cancer stem cells.
Nanog, Sox2, and Oct-4 are transcription factors that are
essential for maintaining the pluripotent embryonic stem
cell phenotype (Boyer et al., 2005). Specifically, Nanog is
essential for establishing and maintaining the pluripotent
state of stem cells (Mitsui et al., 2003); however, the role of
Nanog in the development and progression of malignant
tumors has not been fully determined. Our findings confirmed
those of a previous report (Zbinden et al., 2010), indicating
that Nanog may be a critical factor in GSCs, similar to the case
of ESCs.
We not only found that resveratrol promotes the loss of
self-renewal and increased differentiation of GSCs, but also
elucidated the underlying molecular mechanism. We showed
that resveratrol promotes proteasome-dependent degrada-
tion of Nanog protein. A previous study demonstrated that
NanogmRNA expression is negatively controlled by p53, which
regulates Nanog transcriptional activity (Lin et al., 2005). In
this study, resveratrol treatment enhanced the phosphoryla-
tion and activation of p53 and Nanog mRNA was also
downregulated after resveratrol treatment. These results
suggested that resveratrol-activated p53 might directly
repress Nanog mRNA expression. Even though Nanog mRNA
levels were kept at a constant level at 8 h after commencing
resveratrol treatment, Nanog protein levels were already
reduced by then. Protein stability is one of the possible
mechanisms explaining this discrepancy, as MG132 offsets the
influence of resveratrol-mediated Nanog suppression. We also
demonstrated that Nanog plays an essential role in the
retention of the stemness properties of GSCs; these results
together support the concept that initial downregulation of
Nanog may underlie the effect of resveratrol on GSCs (loss of
self-renewal and induced differentiation). In addition, we
identified that resveratrol activated p53/p21 pathway and
that p53 plays a key role in Nanog degradation induced by
resveratrol treatment. The p53/p21 pathway suppresses the
generation of iPSCs, whereas p53 suppression enhances the
efficiency of iPSC generation (Hong et al., 2009). We showed
that p53-knockdown significantly abrogated resveratrol-
induced suppression of Nanog expression in GSCs. Taken
together with previous reports, our data suggested that
resveratrol-activated p53 may directly repress Nanog expres-
sion through increasing proteasome-dependent degradation
in GSCs. In addition, we tested the efficacy of resveratrol
treatment in GSCs (GS-Y05 and GS-Y07) with functionally
inactive mutant p53 (Fig. S3). In these cells, resveratrol
treatment failed to induce p53 activation, as well as Nanog
suppression and differentiation (Fig. S5). However, Nanog
suppression by siRNA inhibited self-renewal and induced
differentiation (Fig. S6). These results supported that p53 is
a key regulator of resveratrol-induced Nanog suppression and
induction of differentiation of GSCs.
Recent studies have demonstrated that DNA damage could
induce the differentiation of hematopoietic stem cells and
resveratrol induced DNA damage in GSCs (Fig. 4A) (Tyagi
et al., 2011;Wang et al., 2012). Moreover, p53 has been shown
to suppress Nanog expression after DNA damage (Lin et al.,
2005). These findings suggested that DNA damage-induced p53
609p53-Nanog pathway regulates glioma stem cellsactivation might promote GSC differentiation. Thus, the
potential role of DNA damage after resveratrol treatment on
GSC phenotype may become an important subject of future
investigation. In the present study, we also observed differ-
ences in the survival of mice treated with resveratrol or siRNA-
Nanog. Resveratrol downregulates Akt/PKB activity, which
commonly activates and leads to the proliferation
of glioblastoma (Aggarwal et al., 2004; TCGAR, 2008;Woodard
et al., 2010); hence, resveratrol-related improvement of
survival could be via partially Nanog-independent pathways.
This study provides the first evidence that the p53–Nanog
axis that promotes GSC differentiation is one part of the
antitumor effect of resveratrol in GSCs. Resveratrol has
antitumor effects in many types of cancers; thus, the efficacy
of p53–Nanog activation by resveratrol in other cancer
stem cells may become an important subject of future
investigation.Conclusions
In summary, our present data demonstrated that resveratrol
promotes differentiation and inhibits the tumorigenicity
of GSCs. Nanog plays a crucial role in the maintenance of
the self-renewal capacity and induction of differentiation
of GSCs. Moreover, resveratrol was found to induce Nanog
degeneration via p53 activation. Nanog therefore represents
a potential molecular target for developing novel therapeu-
tics to improve the outcomes of patients with glioblastoma.
Resveratrol could be a useful therapeutic agent for cancer
stem/initiating cell-directed glioblastoma therapy.
Supplementary data to this article can be found online at
http://dx.doi.org/10.1016/j.scr.2013.04.004.Acknowledgments
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